Evidence map›Paper›PMID 39201328›Full record

ArticleInternational journal of molecular sciences2024

Specific Deletions of Chromosomes 3p, 5q, 13q, and 21q among Patients with G2 Grade of Non-Small Cell Lung Cancer.

Agata Kolecka-Bednarczyk, Magdalena Frydrychowicz, Bartłomiej Budny, Marcin Ruciński, Claudia Dompe, Piotr Gabryel, Bartosz J Płachno, Marek Ruchała, Katarzyna Ziemnicka, Paweł Zieliński and 1 more

Abstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Agata Kolecka-BednarczykDepartment of Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
Magdalena FrydrychowiczDepartment of Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.ORCID 0000-0002-9428-9583
Bartłomiej BudnyDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland.ORCID 0000-0002-2860-395X
Marcin RucińskiDepartment of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.ORCID 0000-0002-2525-5777
Claudia DompeDepartment of Immunology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
Piotr GabryelDepartment of Thoracic Surgery, Poznan University of Medical Sciences, 60-569 Poznan, Poland.ORCID 0000-0001-6402-8430
Bartosz J PłachnoDepartment of Plant Cytology and Embryology, Institute of Botany, Faculty of Biology, Jagiellonian University in Kraków, 30-387 Cracow, Poland.ORCID 0000-0001-5579-5101
Marek RuchałaDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland.ORCID 0000-0002-6296-7220
Katarzyna ZiemnickaDepartment of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, 60-355 Poznan, Poland.ORCID 0000-0001-5377-8834
Paweł ZielińskiDepartment of Thoracic Surgery, Poznan University of Medical Sciences, 60-569 Poznan, Poland.
Joanna Budna-TukanDepartment of Histology and Embryology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) leads as a primary cause of cancer-related premature mortality in Western populations. This study leverages cutting-edge gene-expression-profiling technologies to perform an in-depth molecular characterization of NSCLC specimens, with the objective of uncovering tumor-specific genomic alterations. By employing DNA microarray analysis, our research aims to refine the classification of NSCLC for early detection, guide molecular-targeted treatment approaches, enhance prognostication, and broaden the scientific understanding of the disease's biology. We identified widespread genomic abnormalities in our samples, including the recurrent loss of chromosomal regions 3p, 5q, 13q, and 21q and the gain of 12p. Furthermore, utilizing Metascape for bioinformatic analysis revealed critical biological pathways disrupted in NSCLC, offering promising leads for novel therapeutic interventions.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedChromosome DeletionChromosomes, Human, Pair 13Chromosomes, Human, Pair 3Chromosomes, Human, Pair 5FemaleGene Expression ProfilingHumansMaleMiddle AgedNeoplasm Gradinggene enrichmentloss of heterozygositylung cancermicroarrays

Identifiers

PMID39201328
PMCPMC11354976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.